Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atopic dermatitis: a new treatment paradigm using pimecrolimus.

Jeffrey M Weinberg1, James G Bowerman, Stuart M Brown

  • 1Department of Dermatology, St. Luke's-Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA. jmw27@columbia.edu

Journal of Drugs in Dermatology : JDD
|July 11, 2003
PubMed
Summary

Pimecrolimus offers a novel, steroid-free treatment for atopic dermatitis (eczema). This review highlights its excellent safety profile and efficacy across all age groups, supporting its use in a new steroid-sparing strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forensic dermatology and the crime scene investigation (CSI) effect: Are jurors influenced by forensic dermatologic investigations that they view on television, printed media, and the internet?

Clinics in dermatology·2026
Same author

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

JAMA dermatology·2025
Same author

Predatory Conferences and Journals in Dermatology Are Black Widow Parties.

Skinmed·2024
Same author

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2024
Same author

Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.

Journal of the American Academy of Dermatology·2024
Same author

Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation.

Journal of the American Academy of Dermatology·2023

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis (AD), or eczema, presents with pruritus, erythema, dry skin, and inflammation.
  • Conventional treatments for AD often involve corticosteroids.

Purpose of the Study:

  • To review atopic dermatitis and its conventional treatments.
  • To discuss pimecrolimus as a novel steroid-free therapeutic option for AD.
  • To propose a steroid-sparing treatment strategy for AD.

Main Methods:

  • Review of existing literature on atopic dermatitis.
  • Analysis of pharmacologic properties, toxicology, and clinical studies of pimecrolimus.
  • Evaluation of safety and adverse events associated with pimecrolimus.

Main Results:

Related Experiment Videos

  • Pimecrolimus demonstrates consistently positive results in infants, children/adolescents, and adults with AD.
  • Pimecrolimus exhibits an excellent safety record with no clinically relevant systemic adverse events.
  • The drug is a viable steroid-free option for AD management.

Conclusions:

  • Pimecrolimus is an effective and safe steroid-free treatment for atopic dermatitis across all age groups.
  • A steroid-sparing strategy incorporating pimecrolimus is proposed for AD management.
  • Further research supports pimecrolimus's role in improving AD treatment paradigms.